MAPT and Alzheimer disease: A positive tau PET is more specific than a positive Aβ plaque for diagnosing AD; cognitively typical patients who have positive Aβ plaques and tau PETs are 20x and 40x more likely to develop mild cognitive impairment (MCI) and dementia, respectively.